Endeavor BioMedicines is a biotechnology company that is striving to discover new ways to treat patients who have life-threatening diseases. The company is working toward that goal by aiming to combat the drivers of fibrosis and oncology, which are both areas of medicine that have unmet needs. Endeavor BioMedicines was founded in 2018 by John Hood and Miguel de los Rios and is headquartered in San Diego, CA. In addition to looking for treatments that alleviate symptoms, Endeavor BioMedicines is seeking ways to reverse the effects of terminal illnesses.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/24/2024 | Series C | $132.58MM | $xx.xx | $676.04MM | Abrdn Inc, Ally Bridge Group, Avidity Partners, Ayurmaya, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, Symbiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
20,320,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Abrdn Inc, Ally Bridge Group, Avidity Partners, Ayurmaya, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, Symbiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners
|
||||||
02/07/2022 | Series B | $101MM | $xx.xx | $353.01MM | Ally Bridge Group, Avidity Partners, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla Capital Management, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
21,415,997
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Ally Bridge Group, Avidity Partners, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla Capital Management, T. Rowe Price
|
||||||
01/07/2021 | Series A-1 | $672,991.65 | $xx.xx | $117.27MM | Longitude Capital, Omega Funds | |
Price per Share
$xx.xx
Shares Outstanding
997,025
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Longitude Capital, Omega Funds
|
||||||
01/07/2021 | Series A-2 | $623,966.61 | $xx.xx | $117.27MM | Longitude Capital, Omega Funds | |
Price per Share
$xx.xx
Shares Outstanding
499,173
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Longitude Capital, Omega Funds
|
||||||
01/07/2021 | Series A-3 | $60.7MM | $xx.xx | $117.27MM | Longitude Capital, Omega Funds | |
Price per Share
$xx.xx
Shares Outstanding
23,917,780
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Longitude Capital, Omega Funds
|